Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy

Lung Cancer

Volumn 45, Issue 3, 2004, Pages 339-348

  Berghmans, T ^a   Lafitte, J J ^b   Thiriaux, J ^c   Vanhoutte, P ^a   Lecomte, J ^c   Efremidis, A ^d   Koumakis, G ^d   Giner, V ^e   Richez, M ^f   Corhay, J L ^f   Wackenier, P ^g   Lothaire, P ^a   Mommen, P ^a   Ninane, V ^h   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier Universitaire de Charleroi   (Belgium)

^d Sint Savas Hospital   (Greece)

^e HOSPITAL DE SAGUNTO   (Spain)

^f Hospital de Sagunto ^*  (Belgium)

^g Centre Hospitalier Universitaire Ambroise Pare   (Belgium)

^h SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy; ELCWP; International staging system; Non small cell lung cancer; Staging system

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; IFOSFAMIDE; MITOMYCIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SODIUM BLOOD LEVEL; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT OUTCOME; VALIDATION PROCESS; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 3843101663     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.02.016     Document Type: Article

References (23)

1. Graziano S.L. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 17(Suppl. 1):1997;S37-S58
2. Denoix P.F. Règles générales de classification des cancers et de présentation des résultats thérapeutiques. Acad. Chir. (Paris). 85:1959;415-424
3. Mountain C.F., Carr D.T., Anderson W.A. A system for the clinical staging of lung cancer. Am. J. Roentgenol. Radium Ther. Nucl. Med. 120:1974;130-138
4. Harmer EM., Classification of malignant tumors. Geneva: Union Internationale Contre le Cancer; 1978. p. 41-45.
5. Mountain C.F. A new international staging system for lung cancer. Chest. 89:1986;225S-233S
6. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717
7. Jassem J., Skokowski J., Dziadziuszko R., Jassem E., Szymanowska A., Rzyman W., et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J. Thorac. Cardiovasc. Surg. 119:2000;1141-1146
8. Andre F., Grunenwald D., Pignon J.P., Dujon A., Pujol J.L., Brichon P.Y., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J. Clin. Oncol. 18:2000;2981-2989
9. Bollen E.C., Theunissen P.H., van Duin C.J., Drenth B.M., van Noord J.A., Blijham G.H. Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand. J. Thorac. Cardiovasc. Surg. 28:1994;97-102
10. Suemasu K.N.T. Prognostic significance of extranodal cancer invasion of mediastinal lymph nodes in lung cancer. Jpn. J. Clin. Oncol. 12:1982;207-212
11. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann. Thorac. Surg. 63:1997;1441-1450
12. Inoue K., Sato M., Fujimura S., Sakurada A., Takahashi S., Usuda K., et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J. Thorac. Cardiovasc. Surg. 116:1998;407-411
13. Leong S.S., Rocha Lima C.M., Sherman C.A., Green M.R. The 1997 international staging system for non-small cell lung cancer: have all the issues been addressed? Chest. 115:1999;242-248
14. Sculier J.P., Paesmans M., Ninane V., Giner V., Bureau G., Lafitte J.J., et al. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. Lung Cancer. 22:1998;201-213
15. Sculier J.P., Lafitte J.J., Berghmans T., Van Houtte P., Lecomte J., Thiriaux J., et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann. Oncol. 15(3):2004;399-409
16. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group Experience. J. Clin. Oncol. 9:1991;1618-1626
17. Glaser C.M., Millesi W., Kornek G.V., Lang S., Schull B., Watzinger F., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;705-715
18. MacRae R., Shyr Y., Johnson D., Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother. Oncol. 64:2002;37-40
19. Oberhoff C., Neri B., Amadori D., Petry K.U., Gamucci T., Rebmann U., et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann. Oncol. 9:1998;255-260
20. Bernardi F.D., Antonangelo L., Beyruti R., Takagaki T., Saldiva P.H., Capelozzi V.L. A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic, and biologic markers. Mod. Pathol. 10:1997;992-1000
21. Kwiatkowski D.J., Harpole D.H., Godleski J., Herndon J.E., Shieh D.B., Richards W., et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J. Clin. Oncol. 16:1998;2468-2477
22. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur. Respir. J. 20:2002;975-981
23. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J. 18:2001;705-719